(BFRG) Bullfrog AI Holdings - Ratings and Ratios

Bullfrog AI Holdings, Inc. is a pioneering digital biopharmaceutical company leveraging artificial intelligence and machine learning to revolutionize the analysis of medical and healthcare data in the United States. By harnessing the power of its proprietary bfLEAP platform, the company provides cutting-edge analytical services to biotechnology and pharmaceutical companies, enabling them to uncover new insights from complex preclinical and clinical data.

The companys robust pipeline includes several promising candidates, such as BF-222, a novel formulation of mebendazole in Phase 1 for the treatment of Glioblastoma, and BF-223, a prodrug of mebendazole in preclinical development for the same indication. Additionally, Bullfrog AI is exploring the potential of BF-114 for the treatment of obesity and chronic liver diseases, as well as Modified HSV-1 for the treatment of colorectal cancer. Strategic licensing agreements with esteemed institutions like George Washington University and Johns Hopkins University further bolster the companys research and development capabilities.

The partnership with the Lieber Institute for Brain Development (LIBD) underscores Bullfrog AIs commitment to developing precision treatments for CNS disorders. With a strong foundation established since its inception in 2017, the company is poised for growth, with its headquarters located in Gaithersburg, Maryland. For more information, visit https://www.bullfrogai.com.

Analyzing the available and , it is evident that Bullfrog AI Holdings, Inc. Common Stock (NASDAQ:BFRG) is a high-risk, high-reward investment opportunity. The stocks current price is $1.85, with a 20-day SMA of $1.79 and a 50-day SMA of $1.73, indicating a potential upward trend. However, the 200-day SMA of $2.26 suggests that the stock is still below its long-term average. Given the companys negative P/E ratio and RoE of -163.22, it is clear that Bullfrog AI is still in a growth phase, with significant investment in research and development. Based on the available data, a potential forecast for the stock price could be a short-term target of $2.50, driven by the companys progress in its clinical trials and the continued growth of its bfLEAP platform. Nevertheless, investors should exercise caution due to the high volatility of the stock, as indicated by its ATR of 0.17 (9.30%).